The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
It will also examine how factors such as age, income, education, and health conditions may affect these levels.
In addition, the study will identify barriers that may make it difficult to use these blood tests in primary care.
The final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.
Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent
Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context.
Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling.
Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant.
Cognitive decline defined by CDR>0.
Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life
Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance/interpretation of the study procedures and/or with future permanence in the study.
Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc).
The study will enroll 250 cognitively unimpaired adults aged 50-75 years, recruited from the patient registry of the Primary Care Team Raval Sud (EAP Raval Sud) in Barcelona, Spain. This primary care center is embedded in the Raval neighborhood of the Ciutat Vella district, one of the most ethnically diverse areas of Barcelona, characterized by a high proportion of foreign-born residents (over 63%)
Cohort
Cross-sectional
Not listed
Plasma levels of Alzheimer's disease blood-based biomarkers across ethnic groups
The contribution of sociodemographic factors, medical comorbidities, and biological variables to observed differences in levels of blood-based biomarkers will be assessed.
Proportion of participants classified as low, intermediate, or high risk for AD pathology by plasma p-tau217 threshold, per ethnic group
Validation of the RUDAS scale in a multi-ethnic primary care population
Coded thematic categories from in-depth interviews on healthcare barriers, dementia stigma, and illness narratives
Click on the lead sponsor to view all of their trials.
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Lead sponsor
Universitat Pompeu Fabra
Collaborator
Hospital del Mar Research Institute (IMIM)
Collaborator
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Collaborator
Hospital del Mar
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
